# EGFR inhibitor rash: pre-emptive skin care, antibiotics and dose changes

Source: https://onco.cc/protocols/egfr-inhibitor-rash-prophylaxis/  
OnCo record `egfr-inhibitor-rash-prophylaxis` (Protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Drugs that block EGFR, such as cetuximab, panitumumab, amivantamab and EGFR tablets for lung cancer, very often cause an acne-like rash. Starting skin care on day one makes a bad rash much less likely: doxycycline or minocycline for the first weeks, moisturiser, sunscreen, and sometimes a mild steroid cream. Tell your team early if it spreads or hurts: a pause or lower dose may help.

## Summary

The MASCC Skin Toxicity Study Group (2011) recommends pre-emptive management for EGFR inhibitor rash because it is frequent and appears in the first 2 to 4 weeks: hydrocortisone 1 per cent with moisturiser and sunscreen twice daily, plus doxycycline 100 mg twice daily (or minocycline 100 mg daily) for the first 6 weeks, based on the randomised STEPP trial. In STEPP (panitumumab, 95 people), protocol-specified grade 2 or worse skin toxicity in 6 weeks fell from 62 to 29 per cent; J-STEPP repeated the result in Japanese patients (62.5 to 21.3 per cent). A 2022 meta-analysis found oral antibiotics reduced grade 2 or worse rash by 40 per cent; topical antibiotics, vitamin K1 cream and sunscreen alone were not significant. For amivantamab, the 2026 US label now recommends the COCOON regimen at initiation: doxycycline or minocycline 100 mg twice daily for 12 weeks, then clindamycin 1 per cent lotion to the scalp for 9 months, a non-comedogenic moisturiser, daily 4 per cent chlorhexidine for hands and feet, and sun protection; in the COCOON trial (amivantamab with lazertinib, 201 people) it reduced grade 2 or worse dermatologic events by week 12 from 75 to 42 per cent. Doubts remain: in a post hoc analysis of the Valentino trial of first-line panitumumab, doxycycline prophylaxis did not significantly lower rash. Dose rules come from labels: panitumumab is withheld for 1 to 2 doses at grade 3 and restarted at 100, 80 then 60 per cent by occurrence. The ESMO 2021 guideline could not be read.

## Fields

- Kind: Protocol
- Last checked: 2026-11-11
- Also known as: EGFR inhibitor rash prophylaxis; acneiform rash; papulopustular rash; pre-emptive doxycycline; pre-emptive skin treatment; cetuximab rash; panitumumab rash; amivantamab skin care; COCOON regimen; STEPP regimen
- Tags: protocol; skin-toxicity; egfr-inhibitor; supportive-care

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/)
- fronts: [Supportive Care & Survivorship](https://onco.cc/fronts/supportive-care/)
- drugs: [Afatinib](https://onco.cc/drugs/afatinib/), [Amivantamab](https://onco.cc/drugs/amivantamab/), [Cetuximab](https://onco.cc/drugs/cetuximab/), [Erlotinib](https://onco.cc/drugs/erlotinib/), [Gefitinib](https://onco.cc/drugs/gefitinib/), [Hydrocortisone](https://onco.cc/drugs/hydrocortisone/), [Lazertinib](https://onco.cc/drugs/lazertinib/), [Osimertinib](https://onco.cc/drugs/osimertinib/), [Panitumumab](https://onco.cc/drugs/panitumumab/)
- terms: [Living with FOLFOX, CAPOX, FOLFIRI and the EGFR antibodies](https://onco.cc/terms/chemotherapy-side-effects-colorectal/), [Rash and skin toxicity (acneiform rash, paronychia)](https://onco.cc/terms/rash-skin-toxicity/)

---
JSON: https://onco.cc/api/v1/entities/egfr-inhibitor-rash-prophylaxis.json